Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer

被引:68
|
作者
Zaravinos, Apostolos [1 ,2 ]
Roufas, Constantinos [1 ,3 ]
Nagara, Majdi [4 ]
de Lucas Moreno, Beatriz [1 ,5 ]
Oblovatskaya, Maria [1 ]
Efstathiades, Christodoulos [2 ,3 ]
Dimopoulos, Christos [2 ,3 ]
Ayiomamitis, Georgios D. [6 ]
机构
[1] European Univ Cyprus, Sch Sci, Dept Life Sci, CY-1516 Nicosia, Cyprus
[2] Ctr Risk & Decis Sci CERIDES, CY-2404 Nicosia, Cyprus
[3] European Univ Cyprus, Dept Comp Sci & Engn, CY-1516 Nicosia, Cyprus
[4] Aix Marseille Univ, Fac Med, INSERM, UMR S 1251,MMG, Marseille, France
[5] European Univ Madrid, Ctr Res Hlth & Life Sci, Madrid 28670, Spain
[6] Tzane Gen Hosp, Surg Dept 1, Piraeus 18536, Greece
关键词
Colorectal cancer; Cytolytic activity; Classically defined neoepitopes; Alternatively defined neoepitopes; Mutation burden; Immune checkpoints; Cancer drivers; CD8(+) T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; ANTI-PD-L1; ANTIBODY; GENOMIC INSTABILITY; CLINICAL IMPACT; SOLID TUMORS; COLON; SURVIVAL;
D O I
10.1186/s13046-019-1372-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMicrosatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC's biology, including neoepitope burden.MethodsWe used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR.ResultsCRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/-II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients' overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts.ConclusionsOverall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Deregulated expression of cryptochrome genes in human colorectal cancer
    Gianluigi Mazzoccoli
    Tommaso Colangelo
    Anna Panza
    Rosa Rubino
    Angelo De Cata
    Cristiana Tiberio
    Maria Rosa Valvano
    Valerio Pazienza
    Giuseppe Merla
    Bartolomeo Augello
    Domenico Trombetta
    Clelia Tiziana Storlazzi
    Gemma Macchia
    Annamaria Gentile
    Francesca Tavano
    Manlio Vinciguerra
    Giovanni Bisceglia
    Valeria Rosato
    Vittorio Colantuoni
    Lina Sabatino
    Ada Piepoli
    Molecular Cancer, 15
  • [22] Deregulated expression of cryptochrome genes in human colorectal cancer
    Mazzoccoli, Gianluigi
    Colangelo, Tommaso
    Panza, Anna
    Rubino, Rosa
    De Cata, Angelo
    Tiberio, Cristiana
    Valvano, Maria Rosa
    Pazienza, Valerio
    Merla, Giuseppe
    Augello, Bartolomeo
    Trombetta, Domenico
    Storlazzi, Clelia Tiziana
    Macchia, Gemma
    Gentile, Annamaria
    Tavano, Francesca
    Vinciguerra, Manlio
    Bisceglia, Giovanni
    Rosato, Valeria
    Colantuoni, Vittorio
    Sabatino, Lina
    Piepoli, Ada
    MOLECULAR CANCER, 2016, 15
  • [23] Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer
    Lijun Xu
    Qing Zheng
    World Journal of Surgical Oncology, 19
  • [24] Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer
    Xu, Lijun
    Zheng, Qing
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [25] High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer
    Kitsou, Mara
    Ayiomamitis, Georgios D.
    Zaravinos, Apostolos
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 57 (01) : 237 - 248
  • [26] Assessment of tumor-infiltrating lymphocytes and immune-checkpoints expression in metastatic colorectal cancer patients
    Gobert, Aurelien
    Mitri, Rana
    Mateescu, Cristian
    Mouawad, Roger
    Le Naour, Gilles
    Bachet, Jean Baptiste
    Dubreuilh, Olivier
    Varinot, Justine
    Khayat, David
    Malouf, Gabriel G.
    Capron, Frederique
    Spano, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] The mutational pattern of cell cycle checkpoints and regulators in Egyptian colorectal cancer patients.
    El-Din Youssef, Amira Salah
    Lotfy, Mai M.
    Nassar, Auhood
    Zekri, Abdel-Rahman N.
    CANCER RESEARCH, 2021, 81 (13)
  • [28] Immune cytolytic activity across various cancer types
    Zaravinos, Apostolos
    Roufas, Konstantinos
    Efstathiades, Christodoulos
    Dimopoulos, Christos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S25 - S25
  • [29] Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
    Schrock, A. B.
    Ouyang, C.
    Sandhu, J.
    Sokol, E.
    Jin, D.
    Ross, J. S.
    Miller, A.
    Lim, D.
    Amanam, I
    Chao, J.
    Catenacci, D.
    Cho, M.
    Braiteh, F.
    Klempner, S. J.
    Ali, S. M.
    Fakih, M.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1096 - 1103
  • [30] Expression Patterns of Immune Checkpoints in Breast Cancer Tumors and Their Margins
    Baradaran, Behzad
    Hoseini, Mostafa Haji Molla
    Mavaddati, Hamid
    Rahbar Farzam, Omid
    Minouei, Mahsa
    Shanehbandi, Daruish
    SSRN,